NCT05859659 Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
| NCT ID | NCT05859659 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yaou Liu |
| Condition | Brain (Nervous System) Cancers |
| Study Type | OBSERVATIONAL |
| Enrollment | 70,000 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70,000 participants in total. It began in 2022-01-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary central nervous system (CNS) tumors, the vast majority (\>90%) occurring in the brain and the remainder occurring in the meninges, spinal cord, and cranial nerves, showing an annual incidence of about 6-8 people per 100,000 population but its effects on health-care systems is out of proportion with incidence due to the substantial high rates of morbidity and mortality. Among which, glioma disease is the most common primary malignant CNS tumor, while the glioblastoma that showed the highest degree of malignancy and the worst prognosis accounts for 70-75%. The construction goal of this project is to construct a multivariate retrospective CNS tumor database (over 50,000 cases, including 10,000 glioma) integrating clinical information, preoperative magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (3,000 cases) integrating advanced magnetic resonance sequences and postoperative follow-up. It aims to form a standardized database integrating magnetic resonance imaging, pathological results, and clinical-prognostic information. Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation, tumor classification and labeling process, and the expert consensus on database construction and use management of CNS tumors were established. We aim to form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms. On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of CNS tumor diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated, and providing comprehensive resources of retrospective data and prospective cohorts for large-scale reasearches, such as classification or treatment intervention predictions.
Eligibility Criteria
Inclusion Criteria: * (1) a clear diagnosis of glioma based on pathological results; * (2) The MRI sequence is complete and there are no obvious artifacts in the image; * (3) The patient signs an informed consent form Exclusion Criteria: * (1) Suffering from other neurological diseases; * (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy; * (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up; * (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.
Contact & Investigator
Yaou Liu, Doctor
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT05859659 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Brain (Nervous System) Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05859659 currently recruiting?
Yes, NCT05859659 is actively recruiting participants. Contact the research team at yaouliu80@163.com for enrollment information.
Where is the NCT05859659 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05859659 clinical trial?
NCT05859659 is sponsored by Yaou Liu. The principal investigator is Yaou Liu, Doctor at Beijing Tiantan Hospital. The trial plans to enroll 70,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.